Denmark Outlines Vision For Decentralized Trials Beyond COVID-19
The Danish medicines regulator has set out its expectations on key elements of decentralized clinical trials as part of Denmark’s ongoing effort to develop a robust regulatory framework in this area.
You may also be interested in...
COVID-19 is driving changes to how clinical trials are being conducted in the US, with 44% of respondents who participated in a recent survey saying they have adapted or plan to become decentralized in coming months.
Danish regulators tell the Pink Sheet they want to know what is holding companies back from submitting applications for decentralized clinical trials and are keen to find creative solutions to possible hurdles.
A new multi-stakeholder alliance wants to improve the adoption of decentralized clinical trials that have already drawn much attention during the COVID-19 pandemic. There are plans to aggregate best practices, share evidence and information, and identify and address key barriers.